The STEP trials demonstrated that semaglutide users achieved an average 1015% body weight reduction over 68 weeks, with some patients losing up to 22% of their starting weight
Semaglutide has shown kidney-protective benefits in clinical trials and is generally safe for patients with stage 3a3b chronic kidney disease (eGFR 3059)
Today, they show up in places many would never have anticipated: in grocery baskets, on beverage aisles, in fashion stock rooms, and in strategic planning decks for global brands
For example, the 4-hour threshold for numerator component (3), boarding time, was developed according to recommendations from TJC and ACEP
You may see a tiny drop of blood or medication at the injection site
Semaglutide, primarily used for managing type 2 diabetes and aiding weight loss, raises concerns among patients and healthcare providers regarding potential liver damage